Search research articles
Contact Us
Filters
Showing results (141-150 of 158) with videos related to
Page
of 16
Sort By:
Molecular Autism
|
February 1, 2017
d-Cycloserine enhances durability of social skills training in autism spectrum disorder
Logan K Wink, Noha F Minshawi, Rebecca C Shaffer, et al.
Journal of Neurodevelopmental Disorders
|
June 16, 2017
Fragile X targeted pharmacotherapy: lessons learned and future directions
Craig A Erickson, Matthew H Davenport, Tori L Schaefer, et al.
Journal of Neurodevelopmental Disorders
|
May 8, 2026
Gaboxadol increases resting theta and alpha power without affecting evoked responses in fragile X syndrome in a home-based setting
Lisa A De Stefano, Hyeonseok Kim, Craig A Erickson, et al.
Journal of the American Academy of Child and Adolescent Psychiatry
|
January 13, 2023
Lymphocytic Extracellular Signal-Regulated Kinase Dysregulation in Autism Spectrum Disorder
Craig A Erickson, Charles R Tessier, Christina Gross, et al.
Journal of Autism and Developmental Disorders
|
November 26, 2013
STX209 (arbaclofen) for autism spectrum disorders: an 8-week open-label study
Craig A Erickson, Jeremy M Veenstra-Vanderweele, Raun D Melmed, et al.
Biorxiv : the Preprint Server for Biology
|
April 1, 2025
A human electrophysiological biomarker of Fragile X Syndrome is shared in V1 of <i>Fmr1</i> KO mice and caused by loss of FMRP in cortical excitatory neurons
Sara S Kornfeld-Sylla, Cigdem Gelegen, Jordan E Norris, et al.
Nature Communications
|
February 9, 2026
A human electrophysiological signature of Fragile X pathophysiology is shared in V1 of Fmr1<sup>-/y</sup> mice
Sara S Kornfeld-Sylla, Cigdem Gelegen, Jordan E Norris, et al.
Communications Biology
|
May 13, 2022
Neocortical localization and thalamocortical modulation of neuronal hyperexcitability contribute to Fragile X Syndrome
Ernest V Pedapati, Lauren M Schmitt, Lauren E Ethridge, et al.
Molecular Genetics & Genomic Medicine
|
July 19, 2022
Descriptive analysis of seizures and comorbidities associated with fragile X syndrome
Igor Albizua, Krista Charen, Lisa Shubeck, et al.
Biomedicines
|
July 27, 2024
Safety, Tolerability, and EEG-Based Target Engagement of STP1 (PDE3,4 Inhibitor and NKCC1 Antagonist) in a Randomized Clinical Trial in a Subgroup of Patients with ASD
Craig A Erickson, Laura Perez-Cano, Ernest V Pedapati, et al.
Page
of 16
Search research articles
Search
Showing results (141-150 of 158) with videos related to
Sort By:
Page
of 16
Molecular Autism
|
February 1, 2017
d-Cycloserine enhances durability of social skills training in autism spectrum disorder
Logan K Wink, Noha F Minshawi, Rebecca C Shaffer, et al.
Journal of Neurodevelopmental Disorders
|
June 16, 2017
Fragile X targeted pharmacotherapy: lessons learned and future directions
Craig A Erickson, Matthew H Davenport, Tori L Schaefer, et al.
Journal of Neurodevelopmental Disorders
|
May 8, 2026
Gaboxadol increases resting theta and alpha power without affecting evoked responses in fragile X syndrome in a home-based setting
Lisa A De Stefano, Hyeonseok Kim, Craig A Erickson, et al.
Journal of the American Academy of Child and Adolescent Psychiatry
|
January 13, 2023
Lymphocytic Extracellular Signal-Regulated Kinase Dysregulation in Autism Spectrum Disorder
Craig A Erickson, Charles R Tessier, Christina Gross, et al.
Journal of Autism and Developmental Disorders
|
November 26, 2013
STX209 (arbaclofen) for autism spectrum disorders: an 8-week open-label study
Craig A Erickson, Jeremy M Veenstra-Vanderweele, Raun D Melmed, et al.
Biorxiv : the Preprint Server for Biology
|
April 1, 2025
A human electrophysiological biomarker of Fragile X Syndrome is shared in V1 of <i>Fmr1</i> KO mice and caused by loss of FMRP in cortical excitatory neurons
Sara S Kornfeld-Sylla, Cigdem Gelegen, Jordan E Norris, et al.
Nature Communications
|
February 9, 2026
A human electrophysiological signature of Fragile X pathophysiology is shared in V1 of Fmr1<sup>-/y</sup> mice
Sara S Kornfeld-Sylla, Cigdem Gelegen, Jordan E Norris, et al.
Communications Biology
|
May 13, 2022
Neocortical localization and thalamocortical modulation of neuronal hyperexcitability contribute to Fragile X Syndrome
Ernest V Pedapati, Lauren M Schmitt, Lauren E Ethridge, et al.
Molecular Genetics & Genomic Medicine
|
July 19, 2022
Descriptive analysis of seizures and comorbidities associated with fragile X syndrome
Igor Albizua, Krista Charen, Lisa Shubeck, et al.
Biomedicines
|
July 27, 2024
Safety, Tolerability, and EEG-Based Target Engagement of STP1 (PDE3,4 Inhibitor and NKCC1 Antagonist) in a Randomized Clinical Trial in a Subgroup of Patients with ASD
Craig A Erickson, Laura Perez-Cano, Ernest V Pedapati, et al.
Page
of 16